PMID- 32163529
OWN - NLM
STAT- MEDLINE
DCOM- 20200629
LR  - 20200629
IS  - 1699-3993 (Print)
IS  - 1699-3993 (Linking)
VI  - 56
IP  - 2
DP  - 2020 Feb
TI  - Mirogabalin besylate in the treatment of neuropathic pain.
PG  - 135-149
LID - 10.1358/dot.2020.56.2.3100504 [doi]
AB  - Neuropathic pain (NeP) is a global cause of suffering and debilitation leading to 
      significant morbidity and reduced quality of life. New treatments are needed to 
      address the growing prevalence of NeP and its impact on sleep, mood and 
      functionality. Mirogabalin besylate (mirogabalin, Tarlige) is a gabapentinoid 
      therapy developed by Daiichi Sankyo which is approved in Japan for the treatment 
      of postherpetic neuralgia and painful diabetic peripheral neuropathy. Mirogabalin 
      has a potent pain-modulating effect with a unique high affinity and prolonged 
      dissociation rate for the a2delta-1 subunit of voltage-gated calcium (Ca2+) 
      channels (VGCCs) on the dorsal root ganglion resulting in more sustained 
      analgesia compared with traditional gabapentinoids. Additionally, mirogabalin has 
      a superior adverse events (AEs) profile due to a rapid dissociation from the 
      a2delta-2 subunit of VGCCs potentially implicated in central nervous 
      system-specific AEs. The most common AEs for mirogabalin are dizziness 
      (approximately 8-16%), somnolence (approximately 6-24%) and headache 
      (approximately 6-14%), with a lower incidence of constipation, nausea, diarrhea, 
      vomiting, edema, fatigue and weight gain. Postmarketing studies are required to 
      evaluate its analgesic durability and efficacy when combined with other 
      antineuropathic agents such as tricyclics, duloxetine and tramadol/tapentadol.
CI  - Copyright 2020 Clarivate Analytics.
FAU - Burgess, J
AU  - Burgess J
AD  - Diabetes and Endocrinology Research, Department of Eye and Vision Sciences, 
      Institute of Ageing and Chronic Disease and the Pain Research Institute, 
      University of Liverpool and Liverpool University Hospital NHS Foundation Trust, 
      Liverpool, UK.
FAU - Javed, S
AU  - Javed S
AD  - Institute of Cardiovascular Sciences, University of Manchester, Manchester, UK.
FAU - Frank, B
AU  - Frank B
AD  - The Walton Centre, Department of Pain Medicine, Liverpool, UK.
FAU - Malik, R A
AU  - Malik RA
AD  - Institute of Cardiovascular Sciences, University of Manchester, Manchester, UK; 
      Weill Cornell Medicine-Qatar, Research Division, Qatar Foundation, Education 
      City, Doha, Qatar.
FAU - Alam, U
AU  - Alam U
AD  - Division of Endocrinology, Diabetes and Gastroenterology, University of 
      Manchester, Manchester, UK. uazman.alam@liverpool.ac.uk, 
      uazman.alam@manchester.ac.uk.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - Spain
TA  - Drugs Today (Barc)
JT  - Drugs of today (Barcelona, Spain : 1998)
JID - 101160518
RN  - 0 (Analgesics)
RN  - 0 (Bridged Bicyclo Compounds)
RN  - S7LK2KDM5U (mirogabalin)
SB  - IM
MH  - Analgesics/*therapeutic use
MH  - Bridged Bicyclo Compounds/*therapeutic use
MH  - Humans
MH  - Neuralgia/*drug therapy
OTO - NOTNLM
OT  - Analgesic drugs
OT  - Mirogabalin besylate
OT  - Neuropathic pain
OT  - Painful diabetic peripheral neuropathy
OT  - Postherpetic neuralgia
OT  - Tarlige
OT  - Voltage-gated calcium channel ligands
EDAT- 2020/03/13 06:00
MHDA- 2020/07/01 06:00
CRDT- 2020/03/13 06:00
PHST- 2020/03/13 06:00 [entrez]
PHST- 2020/03/13 06:00 [pubmed]
PHST- 2020/07/01 06:00 [medline]
AID - 3100504 [pii]
AID - 10.1358/dot.2020.56.2.3100504 [doi]
PST - ppublish
SO  - Drugs Today (Barc). 2020 Feb;56(2):135-149. doi: 10.1358/dot.2020.56.2.3100504.